BTS
NKTR icon

BB&T Securities’s Nektar Therapeutics NKTR Stock Holding History

BB&T Securities’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-531
Closed -$283K – 1669
2019
Q2 		$283K Buy
531
+65
+14% +$32.6K ﹤0.01% 1340
2019
Q1 		$234K Sell
466
-7
-1% -$4.15K ﹤0.01% 1421
2018
Q4 		$233K Sell
473
-292
-38% -$176K ﹤0.01% 1299
2018
Q3 		$698K Buy
765
+334
+77% +$285K 0.01% 945
2018
Q2 		$315K Buy
431
+164
+61% +$189K ﹤0.01% 1260
2018
Q1 		$425K Buy
+267
New +$344K ﹤0.01% 1090

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BB&T Securities's NKTR Position: Q3 2019 in Review

BB&T Securities sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 531 shares — an estimated $283K sold.

BB&T Securities first reported a position in NKTR in Q1 2018 and held it in 6 quarters. The position peaked at $698K in Q3 2018. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • BB&T Securities reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • BB&T Securities sold 531 Nektar Therapeutics shares in Q3 2019, an estimated $283K.
  • BB&T Securities first reported a position in Nektar Therapeutics in Q1 2018 and held it in 6 quarters.
  • BB&T Securities's Nektar Therapeutics position peaked at $698K in Q3 2018.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on BB&T Securities's 13F filing for Q3 2019, filed 30 Oct 2019.